The virtual study also applies predicting heart disease to help researchers better understand earlier treatments for the #1 killer among men and women in the US.

Claudio Marelli, Strategic Medical Leader for GE Healthcare said, “The Framingham score fails to predict 25 percent of coronary artery disease. Unconditional treatment might expose patients to unbeneficial treatments. Our collaboration with Archimedes will shed light on the cost-benefit of new modeling strategies for CHD — and on the value of imaging — to increase current risk stratification capacities to adjust the intensity of treatment accordingly.”

Despite recent progress in the early diagnosis and prevention of CHD, many people continue to be improperly identified through current risk measurement tools such as the Framingham Risk Score. The collaboration will allow for the evaluation of new strategies to determine the potential of an improved model for calculating the risk of CHD based on new technologies and risk factors. “Leading innovators like GE Healthcare are embracing healthcare modeling,” said Barbara Peskin, Principal Investigator for Archimedes. “We are delighted to partner with GE Healthcare in its commitment to investigating preventive health through the use of the Archimedes Model.”